Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HDAC8: a multifaceted target for therapeutic interventions.

Trends in pharmacological sciences - 1 Jul 2015

Chakrabarti Alokta, Oehme Ina, Witt Olaf, Oliveira Guilherme, Sippl Wolfgang, Romier Christophe, Pierce Raymond J, Jung Manfred

Abstract excerpt

Histone deacetylase 8 (HDAC8) is a class I histone deacetylase implicated as a therapeutic target in various diseases, including cancer, X-linked intellectual disability, and parasitic infections. It is a structurally well-characterized enzyme that also deacetylates nonhistone proteins. In cancer, HDAC8 is a major 'epigenetic player' that is linked to deregulated expression or interaction with transcription...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to De Lange Syndrome
Share to Enzyme Activators

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to Histone Deacetylases

Share to Molecular Structure

Share to Repressor Proteins

Share to Schistosomiasis

Share to Structure-Activity Relationship

Source

Identifiers

PMID: 26013035
DOI: 10.1016/j.tips.2015.04.013

Genes

HDAC8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HDAC8: a multifaceted target for therapeutic interventions.PMID 26013035Read ↗

Drugging the Schistosome Zinc-Dependent HDACs: Current Progress and Future PerspectivesSemantic proximity Read ↗

Screening and Phenotypical Characterization of Schistosoma mansoni Histone Deacetylase 8 (SmHDAC8) Inhibitors as Multistage Antischistosomal Agents.Semantic proximity Read ↗

Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)Semantic proximity Read ↗

Medicinal chemistry advances in targeting class I histone deacetylasesSemantic proximity Read ↗

Histone deacetylase inhibitors: a patent review (2009 – 2011)Semantic proximity Read ↗

Unraveling HDAC11: Epigenetic orchestra in different diseases and structural insights for inhibitor designSemantic proximity Read ↗

HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory DiseasesSemantic proximity Read ↗

Role of histone deacetylase inhibitors in non-neoplastic diseasesSemantic proximity Read ↗

Patho-epigenetics: histone deacetylases as targets of pathogens and therapeuticsSemantic proximity Read ↗

Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human DiseasesSemantic proximity Read ↗

Histone Deacetylases As Targets for Antitrypanosomal DrugsSemantic proximity Read ↗

Targeting histone deacetylases for the treatment of cancer and inflammatory diseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.